Neurocrine Biosciences is a biotechnology company focused on neurologic, psychiatric and endocrine-related disorders.
The Company’s three late-stage clinical programs are: elagolix, a gonadotropin-releasing hormone antagonist for women’s health that is partnered with AbbVie Inc.; opicapone, a novel, once-daily, peripherally-acting, highly-selective catechol-o-methyltransferase inhibitor under investigation as adjunct therapy to levodopa in Parkinson’s patients; and INGREZZA™, a novel, once-daily, selective VMAT2 inhibitor under investigation for the treatment of Tourette Syndrome.
Neurocrine utilizes advanced technologies to enhance its drug discovery capabilities and to accelerate the drug development process. Working together, Neurocrine’s chemists, pharmacologists, and biologists strive to create new solutions to unmet medical problems.

Employee Rating

3.9More
TypePublic
HQSan Diego, US
Founded1992
Size (employees)400 (est)+105%
Websiteneurocrine.com
Neurocrine Biosciences was founded in 1992 and is headquartered in San Diego, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Neurocrine Biosciences

Kevin Gorman

Kevin Gorman

CEO
Tim Coughlin

Tim Coughlin

CFO
David-Alexandre Gros

David-Alexandre Gros

President and COO
Eric Benevich

Eric Benevich

Chief Commercial Officer
Julie Cooke

Julie Cooke

Chief People Officer
Show more

Neurocrine Biosciences Office Locations

Neurocrine Biosciences has an office in San Diego
San Diego, US (HQ)
12780 El Camino Real
Show all (1)
Report incorrect company information

Neurocrine Biosciences Financials and Metrics

Neurocrine Biosciences Revenue

Neurocrine Biosciences's revenue was reported to be $161.63 m in FY, 2017
USD

Revenue (Q3, 2018)

151.8m

Gross profit (Q3, 2018)

150.2m

Gross profit margin (Q3, 2018), %

99%

Net income (Q3, 2018)

50.8m

EBIT (Q3, 2018)

54.3m

Market capitalization (17-Jan-2019)

8.0b

Closing stock price (17-Jan-2019)

88.6

Cash (30-Sep-2018)

195.7m
Neurocrine Biosciences's current market capitalization is $8 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

2.9m19.8m15.0m161.6m

Revenue growth, %

(100%)(24%)

Cost of goods sold

1.3m

Gross profit

160.4m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

19.8m15.0m6.3m60.8m71.1m96.9m151.8m

Cost of goods sold

61.0k433.0k950.0k854.0k1.6m

Gross profit

6.3m60.3m70.1m96.1m150.2m

Gross profit Margin, %

99%99%99%99%99%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

44.8m31.0m74.2m83.3m254.7m

Accounts Receivable

31.1m

Inventories

Current Assets

148.5m198.2m384.1m310.4m554.9m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

105.5m37.4m29.0m170.3m132.1m66.4m115.3m86.2m99.8m64.1m309.5m267.8m175.3m166.4m195.7m

Accounts Receivable

6.1m29.8m44.6m42.6m54.1m

Inventories

128.0k242.0k6.1m

Current Assets

221.7m197.6m183.9m405.0m389.4m382.8m401.0m392.0m357.9m239.5m536.8m548.5m513.7m567.7m714.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(46.1m)(60.5m)(88.9m)(141.1m)(142.5m)

Depreciation and Amortization

671.0k827.0k1.0m1.5m2.4m

Inventories

(1.0m)

Accounts Payable

(949.0k)9.8m4.4m27.3m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(11.8m)(25.2m)(41.1m)(1.2m)(25.2m)(59.6m)(19.3m)(59.5m)(96.4m)(78.3m)(138.3m)(149.4m)(41.8m)(47.7m)3.0m

Depreciation and Amortization

178.0k386.0k603.0k495.0k739.0k276.0k600.0k1.0m489.0k1.1m1.7m786.0k1.7m2.7m

Inventories

(128.0k)(242.0k)(3.3m)(3.9m)

Accounts Payable

(1.1m)229.0k2.2m1.3m1.7m4.0m(2.3m)1.2m878.0k(6.9m)627.0k11.1m(7.9m)4.3m15.6m
USDY, 2018

Financial Leverage

2.1 x
Show all financial metrics
Report incorrect company information

Neurocrine Biosciences News and Updates

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2018 Net Product Sales Results and 2019 Program Milestones

SAN DIEGO, Jan. 6, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2018, and key clinical development programs for 2019. Kevin Gorman, Chief Executive Officer of...

Neurocrine Biosciences says trial of Tourette syndrome treatment missed primary goal

Neurocrine Biosciences Inc. said Wednesday a midstage trial of a treatment for Tourette syndrome in children and adolescents failed to meet its primary goal. The Phase IIb study found valbenazine did not meet the primary endpoint of reducing tic severity in young people with moderate to severe vers…

Neurocrine Biosciences Announces Topline Data from Phase IIb T-Force GOLD Study Demonstrating Valbenazine Did Not Meet Primary Endpoint in Pediatric Patients with Tourette Syndrome

SAN DIEGO, Dec. 12, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale (YGTSS) in children...

Neurocrine Biosciences to Present New Data Analyses on the Long-Term Effects of INGREZZA® (valbenazine) in Tardive Dyskinesia Patients with Mood Disorders at the 2018 Annual Psych Congress

SAN DIEGO, Oct. 23, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new data analyses on the long-term effects of INGREZZA® (valbenazine) capsules in adults with tardive dyskinesia (TD) and from RE-KINECT, the largest real-world screening...

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2018 Financial Results

SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, Nov. 5, 2018. Neurocrine will then host a conference call and webcast to discuss its financial ...

Neurocrine Biosciences to Present New Long-Term Data Analyses on INGREZZA® (valbenazine) at the 2018 International Congress of Parkinson's Disease and Movement Disorders

SAN DIEGO, Oct. 1, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present new long-term data analyses on INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia...
Show more
Report incorrect company information

Neurocrine Biosciences Company Life and Culture

Report incorrect company information

Neurocrine Biosciences Frequently Asked Questions

  • When was Neurocrine Biosciences founded?

    Neurocrine Biosciences was founded in 1992.

  • Who are Neurocrine Biosciences key executives?

    Neurocrine Biosciences's key executives are Kevin Gorman, Tim Coughlin and David-Alexandre Gros.

  • How many employees does Neurocrine Biosciences have?

    Neurocrine Biosciences has 400 employees.

  • What is Neurocrine Biosciences revenue?

    Latest Neurocrine Biosciences annual revenue is $161.6 m.

  • What is Neurocrine Biosciences revenue per employee?

    Latest Neurocrine Biosciences revenue per employee is $404.1 k.

  • Who are Neurocrine Biosciences competitors?

    Competitors of Neurocrine Biosciences include Cesca Therapeutics, Celldex Therapeutics and Synthetic Biologics.

  • Where is Neurocrine Biosciences headquarters?

    Neurocrine Biosciences headquarters is located at 12780 El Camino Real, San Diego.

  • Where are Neurocrine Biosciences offices?

    Neurocrine Biosciences has an office in San Diego.

  • How many offices does Neurocrine Biosciences have?

    Neurocrine Biosciences has 1 office.